Jade Biosciences IncQ) expected to post a loss of 43 cents a share - Earnings Preview
Jade Biosciences IncQ) is expected to report a loss of 43 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts maintain a "buy" rating, with a median 12-month price target of $16.50, reflecting a potential upside of 55.6% from the last closing price of $7.32. Recent quarterly performances show mixed results, with several misses and beats in earnings estimates over the past year.
- Jade Biosciences Inc (JBIO.OQ) (JBIO.O) is expected to
show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
- LSEG’s mean analyst estimate for Jade Biosciences Inc is for a loss of 43 cents per share.
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 4 “strong buy” or “buy,” 1 “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Jade Biosciences Inc is $16.50, about 55.6% above its last closing price of $7.32 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -4.55 -8.40 -3.15 Beat 62.5
Dec. 31 2025 -6.65 -8.75 -6.65 Beat 24
Sep. 30 2024 -21.70 -20.39 -19.60 Beat 3.9
Jun. 30 2024 -28.65 -28.77 -30.10 Missed -4.6
Mar. -26.83 -26.77 -29.05 Missed -8.5
31 2024
Dec. 31 2023 -24.80 -24.77 -25.90 Missed -4.6
Sep. 30 2023 -24.42 -24.21 -24.85 Missed -2.7
Jun. 30 2023 -24.63 -24.36 -26.60 Missed -9.2
This summary was machine generated August 8 at 12:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
